Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1, 3-ß-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1, 3-ß-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography(296 views)(PDF public34 views) Della Pepa R, Cerchione C, Pugliese N, Colicchio R, Salvatore P, Sirignano C, Soscia E, Pagano L, Sanguinetti M, Pane F, Picardi M
Supportive Care Cancer (ISSN: 0941-4355), 2018 Jun; 26(6): 1691-1694.
Department of Clinical Medicine and Surgery, Federico II University, Via Sergio Pansini, 5, Naples, 80131, Italy
Department of Molecular Medicine and Medical Biotechnology, Federico II University, Naples, Italy
CEINGE, Biotecnologie Avanzate s.c.ar.l., Naples, Italy
Istituto di Biostrutture e Bioimmagini, Consiglio Nazionale delle Ricerche, Naples, Italy
Institute of Hematology, Università Cattolica del Sacro Cuore, Rome, Italy
Institute of Microbiology, Università Cattolica del Sacro Cuore, Rome, Italy
Department of Advanced Biomedical Science, Federico II University, Naples, Italy
References: Not available.
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1, 3-ß-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography
Not available.
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1, 3-ß-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography
No results.
Diagnostic-driven antifungal approach in neutropenic patients at high risk for chronic disseminated candidiasis: preliminary observations on the role of 1, 3-ß-D-glucan antigenemia and multiphasic contrast-enhanced computed tomography
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(423 views) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 ViewExport to BibTeXExport to EndNote